The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients

Kim Pettersson-Fernholm, Carol Forsblom, Barry Hudson, Markus Perola, Peter J. Grant, Per Henrik Groop

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

The hyperglycemic milieu in diabetes results in the formation of advanced glycation end products (AGEs) that predominantly act through specific receptors, particularly the receptor for AGEs(RAGE). Two functional polymorphisms in the promoter of the RAGE gene (-429 T/C and -374 T/A) and one in the AGE binding domain in exon 3 (G82S) were studied in 996 Finnish type 1 diabetic patients. In patients with poor metabolic control (HbA1c, > 9.5%), the AA genotype of the -374 T/A polymorphism was more common in those with a normal albumin excretion rate than in those with proteinuria (30 vs. 10%, P = 0.01), We observed less coronary heart disease (6 vs. 14%, P < 0.05), acute myocardial infarction (2 vs. 14%, P = 0.01), and peripheral vascular disease (2 vs. 14%, P < 0.05) in patients with the AA genotype of the -374 T/A polymorphism than in those with the TT + TA genotype, Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.

Original languageEnglish
Pages (from-to)891-894
Number of pages4
JournalDiabetes
Volume52
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Proteinuria
Cardiovascular Diseases
Genotype
Genes
Albumins
Gene-Environment Interaction
Advanced Glycosylation End Products
Peripheral Vascular Diseases
Diabetic Nephropathies
Coronary Disease
Exons
Myocardial Infarction
Advanced Glycosylation End Product-Specific Receptor

Keywords

  • AER, albumin excretion rate
  • AGE, advanced glycation end product
  • AM1, acute myocardial infarction
  • CHD, coronary heart disease
  • CVD, cardiovascular disease
  • ESRD, end-stage renal disease
  • PVD, peripheral vascular disease

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. / Pettersson-Fernholm, Kim; Forsblom, Carol; Hudson, Barry; Perola, Markus; Grant, Peter J.; Groop, Per Henrik.

In: Diabetes, Vol. 52, No. 3, 01.03.2003, p. 891-894.

Research output: Contribution to journalArticle

Pettersson-Fernholm, Kim ; Forsblom, Carol ; Hudson, Barry ; Perola, Markus ; Grant, Peter J. ; Groop, Per Henrik. / The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. In: Diabetes. 2003 ; Vol. 52, No. 3. pp. 891-894.
@article{8a9400e255064640b6560ee9e7a6b640,
title = "The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients",
abstract = "The hyperglycemic milieu in diabetes results in the formation of advanced glycation end products (AGEs) that predominantly act through specific receptors, particularly the receptor for AGEs(RAGE). Two functional polymorphisms in the promoter of the RAGE gene (-429 T/C and -374 T/A) and one in the AGE binding domain in exon 3 (G82S) were studied in 996 Finnish type 1 diabetic patients. In patients with poor metabolic control (HbA1c, > 9.5{\%}), the AA genotype of the -374 T/A polymorphism was more common in those with a normal albumin excretion rate than in those with proteinuria (30 vs. 10{\%}, P = 0.01), We observed less coronary heart disease (6 vs. 14{\%}, P < 0.05), acute myocardial infarction (2 vs. 14{\%}, P = 0.01), and peripheral vascular disease (2 vs. 14{\%}, P < 0.05) in patients with the AA genotype of the -374 T/A polymorphism than in those with the TT + TA genotype, Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.",
keywords = "AER, albumin excretion rate, AGE, advanced glycation end product, AM1, acute myocardial infarction, CHD, coronary heart disease, CVD, cardiovascular disease, ESRD, end-stage renal disease, PVD, peripheral vascular disease",
author = "Kim Pettersson-Fernholm and Carol Forsblom and Barry Hudson and Markus Perola and Grant, {Peter J.} and Groop, {Per Henrik}",
year = "2003",
month = "3",
day = "1",
doi = "10.2337/diabetes.52.3.891",
language = "English",
volume = "52",
pages = "891--894",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients

AU - Pettersson-Fernholm, Kim

AU - Forsblom, Carol

AU - Hudson, Barry

AU - Perola, Markus

AU - Grant, Peter J.

AU - Groop, Per Henrik

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The hyperglycemic milieu in diabetes results in the formation of advanced glycation end products (AGEs) that predominantly act through specific receptors, particularly the receptor for AGEs(RAGE). Two functional polymorphisms in the promoter of the RAGE gene (-429 T/C and -374 T/A) and one in the AGE binding domain in exon 3 (G82S) were studied in 996 Finnish type 1 diabetic patients. In patients with poor metabolic control (HbA1c, > 9.5%), the AA genotype of the -374 T/A polymorphism was more common in those with a normal albumin excretion rate than in those with proteinuria (30 vs. 10%, P = 0.01), We observed less coronary heart disease (6 vs. 14%, P < 0.05), acute myocardial infarction (2 vs. 14%, P = 0.01), and peripheral vascular disease (2 vs. 14%, P < 0.05) in patients with the AA genotype of the -374 T/A polymorphism than in those with the TT + TA genotype, Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.

AB - The hyperglycemic milieu in diabetes results in the formation of advanced glycation end products (AGEs) that predominantly act through specific receptors, particularly the receptor for AGEs(RAGE). Two functional polymorphisms in the promoter of the RAGE gene (-429 T/C and -374 T/A) and one in the AGE binding domain in exon 3 (G82S) were studied in 996 Finnish type 1 diabetic patients. In patients with poor metabolic control (HbA1c, > 9.5%), the AA genotype of the -374 T/A polymorphism was more common in those with a normal albumin excretion rate than in those with proteinuria (30 vs. 10%, P = 0.01), We observed less coronary heart disease (6 vs. 14%, P < 0.05), acute myocardial infarction (2 vs. 14%, P = 0.01), and peripheral vascular disease (2 vs. 14%, P < 0.05) in patients with the AA genotype of the -374 T/A polymorphism than in those with the TT + TA genotype, Thus, the association between the RAGE -374 T/A homozygous AA genotype and cardiovascular disease as well as albumin excretion in type 1 diabetic patients with poor metabolic control suggests a gene-environment interaction in the development of diabetic nephropathy and cardiovascular complications.

KW - AER, albumin excretion rate

KW - AGE, advanced glycation end product

KW - AM1, acute myocardial infarction

KW - CHD, coronary heart disease

KW - CVD, cardiovascular disease

KW - ESRD, end-stage renal disease

KW - PVD, peripheral vascular disease

UR - http://www.scopus.com/inward/record.url?scp=0037342124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037342124&partnerID=8YFLogxK

U2 - 10.2337/diabetes.52.3.891

DO - 10.2337/diabetes.52.3.891

M3 - Article

C2 - 12606536

AN - SCOPUS:0037342124

VL - 52

SP - 891

EP - 894

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -